Safety and Durability of AGT103-T Autologous T Cell Therapy for HIV Infection in a Phase 1 Trial

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2022 Dec 1

PMID 36452901

Authors

Nidal Muvarak

Haishan Li

Tyler Lahusen

Jeffrey A Galvin

Princy N Kumar

C David Pauza

Jose Bordon

Affiliations

Soon will be listed here.

Abstract

Clinical Trial Registration: www.clinicaltrials.gov, identifier: NCT03215004.

Citing Articles

Multiple treatment interruptions and protecting HIV-specific CD4 T cells enable durable CD8 T cell response and viral control.

Jain A, Canepa G, Liou M, Fledderman E, Chapoval A, Xiao L Front Med (Lausanne). 2024; 11:1342476.

PMID: 38808136 PMC: 11130509. DOI: 10.3389/fmed.2024.1342476.

Advances in HIV Gene Therapy.

Kitawi R, Ledger S, Kelleher A, Ahlenstiel C Int J Mol Sci. 2024; 25(5).

PMID: 38474018 PMC: 10931721. DOI: 10.3390/ijms25052771.

References

Kalos M . Biomarkers in T cell therapy clinical trials. J Transl Med. 2011; 9:138. PMC: 3170602. DOI: 10.1186/1479-5876-9-138. View

Galperin M, Farenc C, Mukhopadhyay M, Jayasinghe D, Decroos A, Benati D . CD4 T cell-mediated HLA class II cross-restriction in HIV controllers. Sci Immunol. 2018; 3(24). DOI: 10.1126/sciimmunol.aat0687. View

Kervevan J, Chakrabarti L . Role of CD4+ T Cells in the Control of Viral Infections: Recent Advances and Open Questions. Int J Mol Sci. 2021; 22(2). PMC: 7825705. DOI: 10.3390/ijms22020523. View

French M, Lenzo N, John M, Mallal S, McKinnon E, James I . Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med. 2001; 1(2):107-15. DOI: 10.1046/j.1468-1293.2000.00012.x. View

Perez E, Wang J, Miller J, Jouvenot Y, Kim K, Liu O . Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol. 2008; 26(7):808-16. PMC: 3422503. DOI: 10.1038/nbt1410. View

Ahmed R, Adekoya K, Onwuamah C, Oboh B, Iyer S, Oluwatosin A . Mechanism of Viral Suppression among HIV Elite Controllers and Long-Term Nonprogressors in Nigeria and South Africa. Viruses. 2022; 14(6). PMC: 9228396. DOI: 10.3390/v14061270. View

Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E . CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med. 2006; 13(1):46-53. DOI: 10.1038/nm1520. View

Brenchley J, Schacker T, Ruff L, Price D, Taylor J, Beilman G . CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004; 200(6):749-59. PMC: 2211962. DOI: 10.1084/jem.20040874. View

Tebas P, Stein D, Binder-Scholl G, Mukherjee R, Brady T, Rebello T . Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood. 2012; 121(9):1524-33. PMC: 3587318. DOI: 10.1182/blood-2012-07-447250. View

10.

Pauza C, Huang K, Bordon J . Advances in cell and gene therapy for HIV disease: it is good to be specific. Curr Opin HIV AIDS. 2021; 16(2):83-87. DOI: 10.1097/COH.0000000000000666. View

11.

Brenchley J, Ruff L, Casazza J, Koup R, Price D, Douek D . Preferential infection shortens the life span of human immunodeficiency virus-specific CD4+ T cells in vivo. J Virol. 2006; 80(14):6801-9. PMC: 1489023. DOI: 10.1128/JVI.00070-06. View

12.

Benati D, Galperin M, Lambotte O, Gras S, Lim A, Mukhopadhyay M . Public T cell receptors confer high-avidity CD4 responses to HIV controllers. J Clin Invest. 2016; 126(6):2093-108. PMC: 4887161. DOI: 10.1172/JCI83792. View

13.

Addo M, Yu X, Rathod A, Cohen D, Eldridge R, Strick D . Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol. 2003; 77(3):2081-92. PMC: 140965. DOI: 10.1128/jvi.77.3.2081-2092.2003. View

14.

Casado C, Galvez C, Pernas M, Tarancon-Diez L, Rodriguez C, Sanchez-Merino V . Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure. Sci Rep. 2020; 10(1):1902. PMC: 7002478. DOI: 10.1038/s41598-020-58696-y. View

15.

Hu H, Liu F, Kim J, Ratto-Kim S . HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response. Expert Rev Vaccines. 2016; 15(6):709-17. PMC: 4955395. DOI: 10.1586/14760584.2016.1147354. View

16.

Tebas P, Stein D, Tang W, Frank I, Wang S, Lee G . Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014; 370(10):901-10. PMC: 4084652. DOI: 10.1056/NEJMoa1300662. View

17.

Ranasinghe S, Flanders M, Cutler S, Soghoian D, Ghebremichael M, Davis I . HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J Virol. 2011; 86(1):277-83. PMC: 3255877. DOI: 10.1128/JVI.05577-11. View

18.

Hale M, Mesojednik T, Romano Ibarra G, Sahni J, Bernard A, Sommer K . Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells. Mol Ther. 2017; 25(3):570-579. PMC: 5363191. DOI: 10.1016/j.ymthe.2016.12.023. View

19.

Douek D, Brenchley J, Betts M, Ambrozak D, Hill B, Okamoto Y . HIV preferentially infects HIV-specific CD4+ T cells. Nature. 2002; 417(6884):95-8. DOI: 10.1038/417095a. View

20.

Johnson S, Eller M, Teigler J, Maloveste S, Schultz B, Soghoian D . Cooperativity of HIV-Specific Cytolytic CD4 T Cells and CD8 T Cells in Control of HIV Viremia. J Virol. 2015; 89(15):7494-505. PMC: 4505667. DOI: 10.1128/JVI.00438-15. View